Resynthesis of sphingomyelin from plasma-membrane phosphatidylcholine in BHK cells treated with Staphylococcus aureus sphingomyelinase.
About 60-65% of the total sphingomyelin in intact BHK cells is in a readily accessible pool which is rapidly degraded by Staphylococcus aureus sphingomyelinase. No more sphingomyelin is broken down in cells which have been fixed with glutaraldehyde or lysed with streptolysin O, suggesting that all the sphingomyelin which is available to the enzyme is on the cell surface. The inaccessible pool of sphingomyelin does not equilibrate with the plasma-membrane pool, even after prolonged incubation. Experiments using [3H]-choline show that much more phosphocholine is released from the intact cells treated with sphingomyelinase than can be accounted for by breakdown of the original cell-surface pool of sphingomyelin; the excess appears to be a consequence of the breakdown of sphingomyelin newly resynthesized at the expense of a pool of phosphatidylcholine which represents about 8% of total cell phosphatidylcholine and may reside in the plasma membrane. This would be consistent with resynthesis of cell-surface sphingomyelin by the phosphatidylcholine: ceramide phosphocholinetransferase pathway, which has previously been shown to be localized in the plasma membrane. However, in [3H]palmitate-labelled cells there appeared to be no accumulation of the diacylglycerol expected to be produced by this reaction, and no enhanced synthesis of phosphatidate or phosphatidylinositol; instead there was an increased synthesis of triacylglycerol. A similar increase in labelling of triacylglycerol was seen in enzyme-treated cells where the sphingomyelinase was subsequently removed, allowing resynthesis of sphingomyelin which occurred at a rate of about 25% of total sphingomyelin/h. Treatment of BHK cells with sphingomyelinase caused no change in the rates of fluid-phase endocytosis or exocytosis as measured with [3H]inulin.
Allan
D
D
Department of Experimental Pathology, University College, London, U.K.
Quinn
P
P
D001426:Bacterial Proteins; D002478:Cells, Cultured; D002518:Ceramides / Q000378:metabolism; D002794:Choline / Q000378:metabolism; D003902:Detergents / Q000494:pharmacology; D005976:Glutaral / Q000494:pharmacology; D007444:Inulin / Q000493:pharmacokinetics; D050356:Lipid Metabolism; D017830:Octoxynol; D019308:Palmitic Acid; D010169:Palmitic Acids / Q000378:metabolism; D010713:Phosphatidylcholines / Q000378:metabolism*; D010743:Phospholipids / Q000378:metabolism; D010727:Phosphoric Diester Hydrolases / Q000494:pharmacology*; D011092:Polyethylene Glycols / Q000494:pharmacology; D013108:Sphingomyelin Phosphodiesterase / Q000494:pharmacology*; D013109:Sphingomyelins / Q000096:biosynthesis*; D013211:Staphylococcus aureus / Q000201:enzymology; D013301:Streptolysins / Q000494:pharmacology
D001426:Bacterial Proteins; D002518:Ceramides; D003902:Detergents; D010169:Palmitic Acids; D010713:Phosphatidylcholines; D010743:Phospholipids; D013109:Sphingomyelins; D013301:Streptolysins; C025964:streptolysin O; D019308:Palmitic Acid; D011092:Polyethylene Glycols; D017830:Octoxynol; D007444:Inulin; D010727:Phosphoric Diester Hydrolases; D013108:Sphingomyelin Phosphodiesterase; D002794:Choline; D005976:Glutaral